stockrow
Friday 6 November 2026
Export TCRX’s income statement to Excel — free account
TScan Therapeutics, Inc.
TCRX Healthcare Biotechnology
TScan Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.3 million, up 266.7% from fiscal 2024.
- Revenue
- −65.8%
- EPS
- +17.9%
- Free cash flow
- +19.0%
- Total debt
- +1.50%
Quarter to June 2026, against a year earlier
0.18
0.00
0.00%
Follow TCRX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.91 | 14.36 | 12.57 | 28.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.62) | (5.40) | (4.06) | (7.28) | |
P/B ratio |
1.85 | 1.35 | 1.05 | 1.64 | |
Price to Tangible BV |
1.85 | 1.35 | 1.05 | 1.64 | |
EV/Sales |
8.43 | 5.05 | 1.96 | 11.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.52) | (0.38) | (0.15) | (0.72) | |
EV/FCF |
(0.51) | (0.37) | (0.14) | (0.70) | |
Quick Ratio |
3.23 | 6.41 | 8.15 | 6.32 | |
Current Ratio |
3.37 | 6.65 | 8.41 | 6.44 | |
Net Debt/EBITDA |
2.26 | 3.35 | 5.18 | 4.19 | |
Debt/Assets |
19.12% | 16.17% | 14.22% | 12.36% | |
Debt/Equity |
0.47 | 0.34 | 0.26 | 0.23 | |
Asset Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF/Net income |
0.91 | 0.85 | 1.39 | 0.91 | |
Capex/Depreciation |
(0.67) | (0.10) | (0.24) | (1.86) | |
Interest Coverage |
(43.62) | (42.29) | (33.99) | (53.01) | |
Research and Development Expense of Revenue |
2,226.64% | 2,230.55% | 780.64% | 1,262.01% | |
Selling, General and Administrative Expense of Revenue |
774.69% | 836.76% | 248.77% | 313.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
224.26% | 251.02% | 78.22% | 119.91% | |
Graham Net Nets |
0.02 | 0.21 | 0.40 | 0.30 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(92.86%) | (95.05%) | (100.00%) | (61.54%) | |
Free Cash Flow Yield |
(92.98%) | (95.23%) | (107.67%) | (57.49%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF per Share |
(0.21) | (0.19) | (0.25) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.22) | (0.19) | (0.25) | (0.26) | |
Cash per Share |
0.77 | 0.99 | 1.17 | 1.42 | |
Shareholders Equity per Share |
0.53 | 0.75 | 0.95 | 1.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.53 | 0.75 | 0.95 | 1.11 | |
Free Cash Flow |
(28.00) | (24.35) | (32.17) | (33.89) | |
Working Capital |
73.44 | 112.80 | 138.51 | 158.96 | |
Capital Expenditures |
(0.46) | (0.07) | (0.17) | (1.42) | |
Net Current Asset Value |
1.97 | 27.70 | 51.54 | 69.96 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.44 | 0.07 | 0.07 | 0.57 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.83 | 3.63 | 2.76 | 5.00 | |
Average Assets |
235.01 | 267.35 | 299.95 | 305.13 | |
Average Common Equity |
122.87 | 153.56 | 182.05 | 186.55 |
Columns are period end dates · fundamentals updated 26 Oct 2026